Avant Technologies and Austrianova Advancing α-Klotho Cell Therapy as Mayo Clinic Study Links Low α-Klotho Levels to Poor Cardiovascular Survival

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Neutral)

Key Terms

α-Klotho medical

α‑klotho is a naturally occurring protein produced in organs such as the kidneys and brain that helps regulate minerals, cell signaling and processes linked to aging. Think of it as a cellular thermostat that keeps certain body systems in balance; changes in its levels are used as a biomarker and a potential drug target in conditions like kidney disease, heart problems and age-related disorders. Investors watch α‑klotho research because measurements or therapies tied to it can drive diagnostics, treatment development and biotech valuations.

arterial stiffness medical

Arterial stiffness measures how flexible or rigid the body's main blood vessels are; imagine comparing a new, springy garden hose to an old, hard one. Stiffer arteries raise the strain on the heart and are linked to higher risk of heart attack, stroke and other chronic conditions, so changes in arterial stiffness can influence demand for drugs, medical devices, diagnostics, insurance costs and clinical-trial outcomes that matter to investors.

endothelial dysfunction medical

A condition in which the thin inner lining of blood vessels (the endothelium) no longer works properly, impairing its ability to regulate blood flow, block clots, and control inflammation. Like damage to the inner coating of water pipes that makes them stiff, leaky or prone to clogs, it raises risk for heart attacks, strokes and other vascular problems — making it a key target for drugs, devices and diagnostics that can change clinical outcomes, regulatory decisions and market value.

vascular calcification medical

Vascular calcification is the buildup of calcium deposits in blood vessel walls, which makes them stiff and less able to expand and contract like healthy vessels; think of flexible rubber plumbing turning into brittle, calcified pipe. For investors, it matters because the condition is linked to higher rates of heart and kidney complications, driving demand for diagnostics, drugs, and medical devices while also affecting healthcare costs, regulatory review and the commercial prospects of treatments targeting cardiovascular and renal disease.

biomarker medical

A biomarker is a measurable indicator found in the body, such as in blood or tissues, that provides information about health, disease, or how the body responds to treatment. For investors, biomarkers can signal the potential success or risk of medical products or therapies, influencing the value of related companies and industry trends. They act like signals or clues that help assess the progress of medical advancements and their market impact.

genetically modified medical

Organisms whose genetic material has been intentionally changed in a laboratory to add, remove, or alter traits—for example making crops pest-resistant or cells produce a medicine. Investors care because these changes trigger regulatory reviews, patent and licensing issues, supply-chain impacts and consumer acceptance risks; think of it like a product reformulation that can unlock new value but also needs safety clearance and market trust.

cell-based therapy medical

Cell-based therapy uses living cells as the active treatment, delivering them into a patient to replace, repair or instruct damaged tissue or immune responses—think of sending a living repair crew into the body. For investors this matters because these therapies can offer high-value, potentially long-lasting medicines but also come with unique risks and costs tied to complex manufacturing, strict regulation, clinical trial success, and scalability.

peripheral arterial disease medical

Peripheral arterial disease is a condition where fatty buildup and narrowing in the arteries reduce blood flow to the legs and feet, causing pain, slow wound healing, and higher risk of infection. Investors care because PAD drives demand for diagnostics, drugs, medical devices and procedures, influences healthcare costs and reimbursement decisions, and can affect sales, regulatory milestones and long-term revenue for companies in cardiovascular and wound-care markets.

12/09/2025 - 08:00 AM

LAS VEGAS--(BUSINESS WIRE)-- Avant Technologies Inc. (OTCQB: AVAI) (“Avant” or the “Company”), an emerging biotechnology company focused on developing cellbased therapies for diabetes and age-related disorders, today announced a newly published study from the Mayo Clinic reinforces the critical role of the “longevity protein” α-Klotho in vascular health and aging. The research, appearing in the Journal of the American Heart Association, demonstrates a strong association between declining α-Klotho levels and arterial stiffness, endothelial dysfunction, vascular calcification, and significantly reduced patient survival.

The 148-patient study explained:

Low α‐Klotho levels are associated with vascular calcification not only in patients with chronic kidney disease but also in the general population without CKD, highlighting its role in vascular aging.
Low α‐Klotho levels are independently associated with increased mortality, regardless of age, sex, and comorbidities, suggesting that Klotho could serve as a prognostic biomarker for longterm survival.

And the study’s authors concluded, “Further research is needed to unravel the mechanisms through which α-Klotho influences vascular calcification and aging, in order to identify targeted treatments that could prevent or reverse these processes.”

Klothonova, a joint venture company established between Austrianova and Avant, is developing a cutting-edge cell-based therapy designed to address this need by sustainably restoring circulating α-Klotho levels in patients.

The therapy utilizes genetically modified human cells that continuously produce and secrete αKlotho. These cells are encapsulated using Austrianova’s clinically validated Cell-in-a-Box^® technology, which protects the implanted cells from immune rejection while allowing long-term protein delivery.

Dr. Brian Salmons, CEO of Austrianova, said of the study, “This landmark publication by Prof. Amir Lerman’s team at Mayo Clinic provides compelling clinical evidence linking lower αKlotho levels to cardiovascular disease progression and mortality. By encapsulating α-Klothoproducing cells with our proven Cell-in-a-Box^® platform - already demonstrated as safe and effective in human cancer trials - we believe we can meaningfully elevate systemic α-Klotho levels and positively impact cardiovascular disease and other age-related conditions associated with Klotho deficiency.”

Chris Winter, CEO of Avant Technologies, added, “An ever-growing body of scientific literature, including this new Mayo Clinic study, confirms α-Klotho as a master regulator of aging and longevity. The age-related decline in α-Klotho is implicated in a wide range of chronic diseases that appear reversible when Klotho levels are restored. Our encapsulated cell therapy approach has the potential to be a true game-changer - not only for cardiovascular health but for healthy longevity in general.”

The study’s authors also expressed that low Klotho levels are linked to diabetes, peripheral arterial disease, and other age‐related conditions. These conditions often precede more severe cardiovascular diseases, highlighting the importance of Klotho in maintaining vascular integrity and function. Furthermore, Klotho is recognized for its antiaging properties.

Reference: https://www.ahajournals.org/doi/10.1161/JAHA.125.043654

About Avant Technologies

Avant Technologies Inc. is an emerging biotechnology company focused on identifying genetically modified cells lines, and through joint venture and licensing agreements developing innovative cell-based therapies.

About Klothonova

Klothonova is a 50/50 joint venture between Avant Technologies and Austrianova, focused on developing novel cell-based therapies utilizing the Klotho protein for age-related conditions. Headquartered in Las Vegas, Nevada, Klothonova combines expertise in genetic engineering, cell encapsulation, and therapeutic delivery to pioneer sustainable, long-acting treatments.

About Austrianova

Austrianova, based in Singapore, is a leading biotechnology company specializing in clinically proven cell encapsulation, GMP-grade cell products, and cell line development, backed by over 50 peer-reviewed publications and partnerships with global biotech companies.

More information about Avant can be found at https://avanttechnologies.com

You can also follow us on social media at:

https://twitter.com/AvantTechAI
https://www.linkedin.com/company/avant -technologies -ai
https://www.facebook.com/AvantTechAI
https://www.youtube.com/@AvantTechAI

Forward-Looking Statements

Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements because of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date after the date of the press release.